Journey Medical Corporation
DERMJourney Medical Corporation is a commercial-stage pharmaceutical company specializing in the acquisition, development, and commercialization of prescription drugs for dermatological conditions.
Earnings
Next report
Aug 11, 2026 (in a month)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Journey Medical Corporation is a commercial-stage pharmaceutical company specializing in the acquisition, development, and commercialization of prescription drugs for dermatological conditions. The company leverages a dedicated field sales organization to market a portfolio of FDA-approved treatments in the United States, focusing on addressing unmet needs in skin health.
A commercial-stage specialty pharmaceutical firm focused on niche dermatological markets through strategic licensing and a dedicated sales force.
Questions, answered.
- What is Journey Medical Corporation's market cap?
- Journey Medical Corporation (DERM) has a market capitalization of $192.7M and trades on NASDAQ.
- What is Journey Medical Corporation's revenue and profitability?
- Journey Medical Corporation generated $64.7M in trailing twelve-month revenue with a net loss of $9.6M, representing a net margin of -14.8%. Gross margin stands at 65.4%. These figures are based on the Q1 2026 filing.
- Who are Journey Medical Corporation's competitors?
- Journey Medical Corporation's key competitors include Bausch Health Companies Inc., Fortress Biotech, Inc., Pelthos Therapeutics Inc., and others. These companies compete in similar markets and product categories.
- Who does Journey Medical Corporation partner with?
- Journey Medical Corporation's notable partners include Dr. Reddy’s Laboratories, Ltd..
- What subsidiaries does Journey Medical Corporation have?
- Journey Medical Corporation's subsidiaries include Fortress Biotech, Inc..
- Where is Journey Medical Corporation headquartered?
- Journey Medical Corporation is headquartered in United States of America and employs approximately 58 people. It has been publicly traded since 2021.
